TOPLINE:<\/h2>\n
In a cohort of 433 patients receiving metastasis-directed stereotactic radiotherapy (SRT) alongside biological cancer therapy, severe adverse events occurred in less than 10% of cases, with 5.3% experiencing acute events and 6.3% experiencing late events. Uninterrupted biological therapy during SRT was not linked to increased severe adverse events, and interrupting biological therapy was not associated with worse survival outcomes.<\/p>\n
METHODOLOGY:<\/h2>\n\n- Metastases-directed SRT can achieve durable local control of metastases and lead to improved progression-free survival (PFS), but there\u2019s limited evidence on the safety of combining SRT with biological cancer therapy.<\/li>\n
- To better understand the safety profile of this combination, researchers conducted a prospective, multicenter, noninterventional registry cohort study across 27 centers between July 2017 and August 2019, with 24-month follow-up among patients receiving metastases-directed SRT concurrent with biological cancer therapy.<\/li>\n
- Analysis included 514 SRT procedures (271 cranial and 243 extracranial) performed in 433 patients (median age, 62 years), with concurrent therapy defined as treatment within 30 days before or after SRT.<\/li>\n
- Participants received immune checkpoint inhibitors (61.3%), small-molecule drugs (29.2%), or monoclonal antibodies (9.5%), with treatment decisions and radiotherapy dose left to treating clinicians\u2019 discretion.<\/li>\n
- Primary outcome measured severe (grade 3 or higher) adverse events of combined treatment; overall survival and PFS were secondary endpoints.<\/li>\n<\/ul>\n
TAKEAWAY:<\/h2>\n\n- Severe acute adverse events occurred in 5.3% of concurrent treatments (27 of 506), which included three grade 5 events. Severe late adverse events occurred in 6.3% of patients (29 of 459), which included two grade 5 events.<\/li>\n
- Continuing biological therapy during SRT was associated with an overall survival benefit compared with interrupted or delayed biological therapy (median of 31 months vs 20 months; P<\/em> = .046), though the comparison was no longer statistically significant after adjusting for performance status (hazard ratio, 0.81; P\u00a0<\/em>= .17).<\/li>\n
- There was no statistically significant association between uninterrupted biologic therapy during SRT and severe acute or late adverse events, but the analysis did suggest a higher likelihood for adverse events in this group (odds ratio, 2.32; 95% CI, 0.87-6.22).<\/li>\n
- Median PFS was 7 months (95% CI, 6-9 months), with no significant difference between continued vs interrupted\/delayed biological therapy groups.<\/li>\n<\/ul>\n
IN PRACTICE:<\/h2>\n
In this cohort study, continuing biological cancer therapy during SRT was not associated with an increased risk for severe adverse events, the authors concluded. \u201cThese findings suggest a favorable safety profile of metastases-directed SBRT [stereotactic body radiation therapy] in combined modality treatment settings.\u201d<\/p>\n
SOURCE:<\/h2>\n
This study, led by Esm\u00e9e L. Looman, MD, and Stephanie G. C. Kroeze, MD, PhD, University Hospital Zurich in Zurich, Switzerland, was published online on January 14 in JAMA Network Open<\/em>.<\/p>\nLIMITATIONS:<\/h2>\n
This study\u2019s heterogeneous data only allowed for exploratory analyses in subcohorts. Because adverse events were only recorded for the combination of biological cancer therapy and SRT, it was challenging to assess the magnitude of possible added adverse events due to treatment interactions. Additionally, for intracranial metastases, certain symptoms like cerebral edema, seizures, and cognitive disturbance could be attributed to either radiation necrosis or disease progression, making it difficult to determine the exact cause.<\/p>\n
DISCLOSURES:<\/h2>\n
This study was funded by Varian, a Siemens Healthineers Company. The sponsor had no role in the study design, data collection, analysis, manuscript preparation, or publication decision. Multiple authors reported receiving personal fees and grants from various organizations including Varian Medical Systems, Elekta, Zeiss Meditec, Bristol Myers Squibb, AstraZeneca, Merck, Roche, Merck Sharp & Dohme, Sanofi, and Icotec AG outside the submitted work. Additional disclosures are noted in the original article.<\/p>\n
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/em><\/p>\n<\/div>\n<\/div>\n
\n
<<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
TOPLINE: In a cohort of 433 patients receiving metastasis-directed stereotactic radiotherapy (SRT) alongside biological cancer therapy, severe adverse events occurred in less than 10% of cases, with 5.3% experiencing acute events and 6.3% experiencing late events. Uninterrupted biological therapy during SRT was not linked to increased severe adverse events, and interrupting biological therapy was not […]<\/p>\n","protected":false},"author":1,"featured_media":1521,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-1520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/01\/gty-260114-radiation-therapy-treatments-800x450.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/1520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=1520"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/1520\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/1521"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=1520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=1520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=1520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
TAKEAWAY:<\/h2>\n\n- Severe acute adverse events occurred in 5.3% of concurrent treatments (27 of 506), which included three grade 5 events. Severe late adverse events occurred in 6.3% of patients (29 of 459), which included two grade 5 events.<\/li>\n
- Continuing biological therapy during SRT was associated with an overall survival benefit compared with interrupted or delayed biological therapy (median of 31 months vs 20 months; P<\/em> = .046), though the comparison was no longer statistically significant after adjusting for performance status (hazard ratio, 0.81; P\u00a0<\/em>= .17).<\/li>\n
- There was no statistically significant association between uninterrupted biologic therapy during SRT and severe acute or late adverse events, but the analysis did suggest a higher likelihood for adverse events in this group (odds ratio, 2.32; 95% CI, 0.87-6.22).<\/li>\n
- Median PFS was 7 months (95% CI, 6-9 months), with no significant difference between continued vs interrupted\/delayed biological therapy groups.<\/li>\n<\/ul>\n
IN PRACTICE:<\/h2>\n
In this cohort study, continuing biological cancer therapy during SRT was not associated with an increased risk for severe adverse events, the authors concluded. \u201cThese findings suggest a favorable safety profile of metastases-directed SBRT [stereotactic body radiation therapy] in combined modality treatment settings.\u201d<\/p>\n
SOURCE:<\/h2>\n
This study, led by Esm\u00e9e L. Looman, MD, and Stephanie G. C. Kroeze, MD, PhD, University Hospital Zurich in Zurich, Switzerland, was published online on January 14 in JAMA Network Open<\/em>.<\/p>\nLIMITATIONS:<\/h2>\n
This study\u2019s heterogeneous data only allowed for exploratory analyses in subcohorts. Because adverse events were only recorded for the combination of biological cancer therapy and SRT, it was challenging to assess the magnitude of possible added adverse events due to treatment interactions. Additionally, for intracranial metastases, certain symptoms like cerebral edema, seizures, and cognitive disturbance could be attributed to either radiation necrosis or disease progression, making it difficult to determine the exact cause.<\/p>\n
DISCLOSURES:<\/h2>\n
This study was funded by Varian, a Siemens Healthineers Company. The sponsor had no role in the study design, data collection, analysis, manuscript preparation, or publication decision. Multiple authors reported receiving personal fees and grants from various organizations including Varian Medical Systems, Elekta, Zeiss Meditec, Bristol Myers Squibb, AstraZeneca, Merck, Roche, Merck Sharp & Dohme, Sanofi, and Icotec AG outside the submitted work. Additional disclosures are noted in the original article.<\/p>\n
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/em><\/p>\n<\/div>\n<\/div>\n
\n
<<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
TOPLINE: In a cohort of 433 patients receiving metastasis-directed stereotactic radiotherapy (SRT) alongside biological cancer therapy, severe adverse events occurred in less than 10% of cases, with 5.3% experiencing acute events and 6.3% experiencing late events. Uninterrupted biological therapy during SRT was not linked to increased severe adverse events, and interrupting biological therapy was not […]<\/p>\n","protected":false},"author":1,"featured_media":1521,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-1520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/01\/gty-260114-radiation-therapy-treatments-800x450.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/1520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=1520"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/1520\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/1521"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=1520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=1520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=1520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
IN PRACTICE:<\/h2>\n
In this cohort study, continuing biological cancer therapy during SRT was not associated with an increased risk for severe adverse events, the authors concluded. \u201cThese findings suggest a favorable safety profile of metastases-directed SBRT [stereotactic body radiation therapy] in combined modality treatment settings.\u201d<\/p>\n
SOURCE:<\/h2>\n
This study, led by Esm\u00e9e L. Looman, MD, and Stephanie G. C. Kroeze, MD, PhD, University Hospital Zurich in Zurich, Switzerland, was published online on January 14 in JAMA Network Open<\/em>.<\/p>\n This study\u2019s heterogeneous data only allowed for exploratory analyses in subcohorts. Because adverse events were only recorded for the combination of biological cancer therapy and SRT, it was challenging to assess the magnitude of possible added adverse events due to treatment interactions. Additionally, for intracranial metastases, certain symptoms like cerebral edema, seizures, and cognitive disturbance could be attributed to either radiation necrosis or disease progression, making it difficult to determine the exact cause.<\/p>\n This study was funded by Varian, a Siemens Healthineers Company. The sponsor had no role in the study design, data collection, analysis, manuscript preparation, or publication decision. Multiple authors reported receiving personal fees and grants from various organizations including Varian Medical Systems, Elekta, Zeiss Meditec, Bristol Myers Squibb, AstraZeneca, Merck, Roche, Merck Sharp & Dohme, Sanofi, and Icotec AG outside the submitted work. Additional disclosures are noted in the original article.<\/p>\n This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.<\/em><\/p>\n<\/div>\n<\/div>\n TOPLINE: In a cohort of 433 patients receiving metastasis-directed stereotactic radiotherapy (SRT) alongside biological cancer therapy, severe adverse events occurred in less than 10% of cases, with 5.3% experiencing acute events and 6.3% experiencing late events. Uninterrupted biological therapy during SRT was not linked to increased severe adverse events, and interrupting biological therapy was not […]<\/p>\n","protected":false},"author":1,"featured_media":1521,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-1520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/01\/gty-260114-radiation-therapy-treatments-800x450.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/1520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=1520"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/1520\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/1521"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=1520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=1520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=1520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}LIMITATIONS:<\/h2>\n
DISCLOSURES:<\/h2>\n
\n
<<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"